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Abstract
Background: Survival or outcome information is important for clinical routine as well as for clinical research and
should be collected completely, timely and precisely. This information is relevant for multiple usages including quality
control, clinical trials, observational studies and epidemiological registries. However, the local hospital information
system (HIS) does not support this documentation and therefore this data has to generated by paper based or
spreadsheet methods which can result in redundantly documented data. Therefore we investigated, whether
integrating the follow-up documentation of different departments in the HIS and reusing it for survival analysis can
enable the physician to obtain survival curves in a timely manner and to avoid redundant documentation.
Methods: We analysed the current follow-up process of oncological patients in two departments (urology,
haematology) with respect to different documentation forms. We developed a concept for comprehensive survival
documentation based on a generic data model and implemented a follow-up form within the HIS of the University
Hospital Muenster which is suitable for a secondary use of these data. We designed a query to extract the relevant data
from the HIS and implemented Kaplan-Meier plots based on these data. To re-use this data sufficient data quality is
needed. We measured completeness of forms with respect to all tumour cases in the clinic and completeness of
documented items per form as incomplete information can bias results of the survival analysis.
Results: Based on the form analysis we discovered differences and concordances between both departments. We
identified 52 attributes from which 13 were common (e.g. procedures and diagnosis dates) and were used for the
generic data model. The electronic follow-up form was integrated in the clinical workflow. Survival data was also
retrospectively entered in order to perform survival and quality analyses on a comprehensive data set. Physicians
are now able to generate timely Kaplan-Meier plots on current data. We analysed 1029 follow-up forms of 965
patients with survival information between 1992 and 2010. Completeness of forms was 60.2%, completeness of
items ranges between 94.3% and 98.5%. Median overall survival time was 16.4 years; median event-free survival
time was 7.7 years.
Conclusion: It is feasible to integrate survival information into routine HIS documentation such that Kaplan-Meier
plots can be generated directly and in a timely manner.
Background
Accurate survival or outcome information is important
for many clinical studies, clinical routine and epidemiol-
ogy. The standard method for estimating survival is the
Kaplan-Meier plot (KM-plot) [1] with high relevance in
medical research. Particularly in oncology the Kaplan-
Meier technique is used to compare survival information
between different therapy strategies or stages of the dis-
ease [2]. Survival time and follow-up status are used to
compute an estimate of a survival curve for censored
data.
In the German healthcare system a distinction can be
made between the routine documentation which is com-
monly performed in hospital information systems or still
paper based and the research documentation mainly
performed in electronic data capture systems (EDC) or
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eral systems in healthcare resulting in separate docu-
mentation of medical routine, research and quality
management data. In the context of clinical studies sur-
vival information is currently captured on paper based
CRF and occasionally on electronic CRF (eCRF), but
generally separated from HIS. However, some patients
already have at least a basic electronic medical record
[3]. Currently survival analysis is not possible within the
HIS as the required data is not available. A problem of
these external databases consists in the resulting difficult
multiple usage of information. Data from a single
patient can be relevant for several studies (e.g. therapy
study, biomarker discovery study, epidemiological stu-
dies) in addition to clinical routine. Redundant docu-
mentation is common but inefficient regarding a
resource limited setting and carries the danger of incon-
sistent information. In this setting it would be attractive
to use health data outside of direct care delivery. A sec-
ondary use of documented data for research and quality
management [4] may be of potential benefit for those
physicians who already use electronic documentation
[5]. For instance, the idea of the REUSE project implies
that clinical data should be based in the electronic
health record (EHR) independent from the context, in
which data is captured [6]. The secondary use of clinical
data has enormous potential for improving quality of
care [7,8].
Furthermore, there is heterogeneity in the required
follow-up documentation depending on the disease and
the department in which the data is obtained. Physicians
need further information to interpret the status in com-
bination with clinical data. Also, the parameter values
for the follow-up status may be different between onco-
logical diseases. Therefore, an efficient implementation
should be based on a generic data model which is suita-
ble for several diseases.
Studies of health services research, epidemiological
studies and phase III/IV studies often consist of a high
number of cases resulting in laborious documentation
and high data management costs. Using routine docu-
mentation may reduce the documentation workload and
reduce costs. To reach these goals the respective source
data have to be “accurate, legible, contemporaneous, ori-
ginal, attributable, complete and consistent” [9].
However, data quality of follow-up documentation is
often unsatisfactory [10] and requires adaption before it
can be used for research. The follow-up documentation
needs to be complete to obtain meaningful KM-plots as
incomplete information can bias the analysis of the
results [11]. One strategy to increase completeness and
achieve higher data quality is to use an electronic docu-
mentation tool [12,13]. This approach could be
extended to use the HIS for clinical and research
documentation which would also result in high data
quality [14]. Commercial HIS usually cover only events
during hospitalisation so there is a need for a special
follow-up module to allow the survival documentation
for inpatients and outpatients.
With respect to clinical quality management it is
important to obtain timely KM-plots of all patients and
not just from those in clinical studies. Thus, it would be
desirable to integrate the follow-up documentation into
clinical routine and document it in the EHR within the
HIS. Using this method, it will be made available for all
treating physicians and clinical research projects can be
combined with routine documentation by reusing the
EHR [15].
Because of the high relevance, especially in oncology,
we analyse whether an integrated follow-up documenta-
tion is feasible and focus on the following objectives:
1. Is it feasible to design a follow-up documentation
system in the HIS which is suitable for several onco-
logical diseases and provides a secondary use of
data?
2. Is it possible to extract survival information from
routine HIS documentation so that physicians can
obtain KM-plots in a timely manner?
3. What level of data quality can be achieved with
respect to completeness of forms and completeness
of items per form?
Methods
Process analysis
We analysed the current follow-up documentation pro-
cess in the urology and haematology department at the
University Hospital Muenster. Physicians were inter-
viewed to identify weak points and requirements during
the follow-up appointments.
Form analysis
During the form analysis we investigated the attributes
which characterise the overall survival (OS) and the
event-free survival (EFS). We compared follow-up docu-
mentation of two tumours regarding type, complexity
and concordances.
Concept, data model and implementation
We developed a concept for comprehensive survival
documentation based on a generic data model which is
described in the CDISC Operational Data Model (ODM
v1.3.1.) [16] using SNOMED CT V3 Codes [17]. Based
on this concept an electronic survival form was imple-
mented within the local HIS containing specialised parts
for leukaemia and for prostate cancer. We used the inte-
grated tools of the HIS (ORBIS
® from Agfa Healthcare)
[18] to create a form which contains all relevant survival
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workflow.
Data export and survival analysis
We created a report of the HIS form to extract follow-
up information (initial diagnosis date, initial therapy
date, date of last contact, status at the last contact, etc.)
from the HIS and to transfer pseudonymized data sets
to statistical programs. This report was integrated in the
HIS in such a way that it can be used by the physicians
to view summarized data of their patients in the HIS or
to export pseudonymized survival data as comma sepa-
rated values (CSV). Survival analyses were implemented
in R (version 2.10.1) and for the KM-plots we used the
“survfit function” of the R survival library [19]. Differ-
ences between subgroups of patients were assessed
using log-rank test, implemented in the “survdiff func-
tion”. A batch script was written to execute the R survi-
val function in such a way that survival curves and data
quality information are directly accessible in a PDF-file.
Analysing data quality
We analysed completeness to describe data quality
according to Chan et al [20]. Therefore, we designed a
report to query missing and incomplete forms. Based on
these export data, completeness of forms (reference: all
prostate cancer patients in urology) and completeness of
documented items per form were analysed.
The study was performed in compliance with the
World Medical Association Declaration of Helsinki on
Ethical Principles for Medical Research Involving
Human Subjects. HIS data access was approved by the
responsible data protection officer, only de-identified
data items were exported.
Results
Process analysis of the paper based follow-up
documentation
Follow-up documentation was paper based for AML
patients in haematology and spreadsheet based for prostate
cancer patients in urology. In both departments, forms
were completed when patients were appointed to follow-
up examinations. If the patient lacked a follow-up date the
treating physicians could obtain the information from gen-
eral practitioners, from the epidemiology cancer registry or
from the registration office (in case of fatality). For statisti-
cal analysis and survival curves the follow-up documenta-
tion was entered manually into spreadsheets or statistical
programs which were then used to generate KM-plots.
Form analysis
Each department has its own follow-up form. While ana-
lysing both forms we identified 13 common attributes.
Particularly the relevant survival information (diagnosis
date, therapy date, follow-up status and follow-up date)
are common to both departments so that a generic form
for both diseases is possible. The remaining attributes of
both departments were not included in the generic data
model but belong to the disease specific documentation
which is considered in a specialised part of the form.
Table 1 shows the results of the form analysis.
Two of the common attributes (study, status) have dif-
ferent parameter values. For example, the values of the
status lists differed between the two departments con-
sidering the different stages of the diseases. Therefore
we implemented a catalogue with variable parameter
values for each department. For the KM-plots it is only
relevant to distinguish between overall survival (OS –>
yes/no) and event free survival (EFS –> yes/no). There-
fore, we mapped the more detailed elements of the sta-
tus list unambiguously to these two parameters. The
resulting status list with the mapping and coding is pre-
sented in table 2. It is now possible to use this encoding
in both departments for Kaplan-Meier plots.
Concept and data model
Based on the results of the form analysis we developed a
generic data model which includes the 13 common
attributes. These attributes were determined through
data types and also tagged with SNOMED CT codes.
For the specification of the data model we used CDISC
ODM because it is designed to facilitate interchange of
metadata and data for clinical research [16]. The ODM
follow-up form consists of 5 item groups (identity, diag-
nosis, therapy, study data and follow-up data). An
extract of this form is shown in figure 1. The complete
ODM example of the follow-up form can be found in
the supplement (see Additional file 1). All items are spe-
cified by name, id and data type. For all attributes we
added SNOMED CT codes so that the used concepts
are well-defined. Regarding the different status values
and the different study lists in each department we
modelled code tables for the parameter values of the fol-
low-up status. Finally we obtained a system independent
specification for the follow-up form, which also allows
semantic interoperability through the SNOMED codes.
Implementation
Based on the generic data model we implemented a
follow-up form within our HIS (ORBIS
®) and introduced
Table 1 Results of the form analysis
Department #Pages #Attributes (total) #Attributes (common)
Urology 1 35 13
Haematology 1 30 13
Follow-up forms from both departments contain more than 30 attributes to
document survival information, 13 of which are common (e.g. diagnosis date,
therapy date, follow-up date, follow-up status).
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cer patients in the urology department and for AML
patients in the haematology department. An extract of
the implemented HIS form, used for routine documenta-
tion, is shown in figure 2. For each patient the initial
diagnosis and initial therapy can be specified with date,
text and classification. Hence, both points of time can be
used as start date of the KM-plots. The lower part of the
form contains the date of the last visit with the associated
status and provides the possibility to document the
source of the survival information (e.g. general practi-
tioner, registration office). In addition the participation in
clinical studies can be documented. We also added dis-
ease specific sub-forms for prostate cancer and AML
containing the attributes which were not common in
both departments. These forms complete the follow-up
documentation in both departments.
In routine documentation the follow-up form should
be completed for every cancer patient in the respective
department. Patients with prostate cancer or leukaemia
have regular follow-up examination and during those
visits the survival information is documented. If patients
do not appear the information has to be collected from
the current practitioner. In this case physicians and
study nurses enquire relevant information from general
practitioners as well as the registration office (if there is
a fatality reported) and enter this information into the
system. We also added the attribute “source” so that the
documenting physician can document the enquired
institution. In this manner information from outpatients
can be also documented. In addition to this generic
form, disease and department specific attributes can be
documented in specific form components which were
provided for prostate cancer and leukaemia. To analyse
the feasibility of KM-plots based on structured HIS data
the form was integrated in the clinical workflow in the
urology department and during a short time frame data
from follow-up patients was documented. To achieve a
high number of cases which allow for comprehensive
analyses and to reuse previously existing survival data
from paper based records or spreadsheet files in the
urology department this information was retrospectively
transferred to the HIS. In the haematology department
up until now the electronic follow-up documentation
was only used in a pilot installation with relatively few
patients. Therefore, the following analyses are based on
urology data. In our approach we provide one form per
follow-up date so that each patient has several forms
during the course of his disease. The current survival
status is always taken from the most current form.
HIS-based Kaplan-Meier
The documented survival data were extracted from the
EHR and analysed with the statistic software R. We con-
sidered a follow-up period from 03.06.1992 to
31.05.2010 in which patients where documented and
completed follow-up forms also retrospectively to obtain
a relevant data basis for the KM-plots. In total follow-
up forms were entered from 23
rd February to 01
st July
2010 for 1029 patients; 223 of them were completed in
the routine documentation process, 806 were entered
retrospectively. Using the R survival library we imple-
mented survival analyses and KM-plots based on
exported CSV-data. First we removed all duplicated
forms from all patients and kept only the data from the
most current form. Observation time was defined on
basis of therapy start date and follow-up date, overall
survival and event-free survival were computed concern-
ing the following status encodings (table 2). We created
data frames for the EFS and OS for the patient collective
Table 2 Status values in the department of haematology and urology
Status in the haematology department (AML) Status in the urology department (prostate cancer) OS EFS
Initial diagnosis Initial diagnosis 0 0
- Relapse free 0 0
Aplasia - 0 0
First remission - 0 0
Complete remission unconfirmed - 0 0
Second remission - 0 0
Relapse Relapse (PSA) 0 1
- Relapse (imaging) 0 1
Persistent AML - 0 1
Death of AML Death of prostate cancer 1 1
Death independent from AML Death independent from prostate cancer 1 1
Death of unknown cause Death of unknown cause 1 1
Both departments have different status list values to be considered in the survival analysis. Concerning overall survival (OS) analysis all death events are coded as
1, regarding event-free survival (EFS) analysis all except for initial diagnosis and relapse free are coded as 1.
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cancer patients were divided into two groups. KM-plots
with numbers at risk were generated from all four data
frames. The complete R code can be found in the sup-
plement (see Additional file 2).
Survival information was available for 881 of the 965
patients. The median overall survival time was 16.4
years, the median event-free survival time was 7.7 years.
The probability of 5-year overall survival was 98.2%
(EFS: 82.8%), the probability of a 10-year overall survival
was 89.9% (EFS: 32.6%). Table 3 shows the basic infor-
mation of patients in the urology department.
Based on these survival data from HIS the following
KM-plots (figure 3+4) were created. Figure 3 shows the
overall and the event free survival with a 95% confidence
interval of all prostate cancer patients documented in the
Figure 1 Extract of the follow-up representation in CDISC ODM. The extract shows the definition of diagnosis and therapy data with their
data type. The complete ODM example of the follow-up form can be found in the supplement (see Additional file 1).
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group analyses. To differentiate between the patients it is
possible to combine survival data with other routine
information (e.g. biopsy information, lab results, body
weight, height, ultra sound findings) available in the EHR.
We wrote a batch script to automate the process from
the export file to the final PDF with the KM-plots. Dur-
ing several discussions with health professionals we
discovered that there are patients for whom no accurate
date of relapse or freedom of relapse can be specified.
To handle this, the generic data model was adapted to
allow for imprecise inputs (e.g. Oct. 2008, 2007).
Data quality
Based on the exported data sets we assessed complete-
ness of the documentation to describe data quality.
Figure 2 Extract of the follow-up form. Initial diagnosis and initial therapy can be documented with date, text and classification in the upper
part of the form. The lower part contains the date of the last visit with the associated status in addition to the studies. This figure shows the
electronic version of the AML follow-up documentation. All attributes are similar for prostate cancer but status lists and studies have different
parameter values. In addition to this generic form, disease specific form components can be provided.
Table 3 Survival information of patients in the urology department
Department of urology Analysis of overall survival Analysis of event-free survival
Number of patients 965 965
Survival information available 881 881
Median survival time (years) 16.4 7.7
Probability of 5-year survival (percent) 98.2 82.8
Probability of 10-year survival (percent) 89.9 32.6
Total number of events 31 267
->Death 31 31
->Relapse - 236
Survival information was available for 881 patients covering a time interval of nearly 17 years.
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analyses we used R to identify missing items of the sur-
vival parameters used for the KM-plots (therapy start
date, follow-up status and follow-up date). These reports
are permanently installed so that data quality may be
obtained also for future analyses and interpretation of
the KM-plots. Concerning the documented items per
form, we distinguished between routine cases and retro-
spective cases and measured also the completeness of
the whole data set. During the routine documentation
the completeness of all items was 86.6% due to a few
missing follow-up dates. Considering only retrospec-
tively entered data we reached a completeness of 92.4%.
In total, the completeness in the follow-up date was
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Figure 3 Kaplan-Meier Plots. These figures show the survival with 95% confidence interval and numbers at risk. The left figure represents
overall survival and the right figure event-free survival of patients with prostate cancer after radical prostatectomy.
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Figure 4 Kaplan-Meier Plots (Group analysis). These figures show the survival of the prostate cancer patients divided into two groups with
numbers at risk. The left figure represents overall survival with no significant difference (p = 0.552) and the right figure event-free survival which
shows a significant difference between both patient groups (p < 0.001).
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Page 7 of 10high (~94.3%) while completeness of therapy start date
and follow-up status was very high (> 97%). KM-plots
based on all three attributes were available for 881
patients (91.3%). Table 4 shows the results.
To analyse the acceptance of the electronic forms we
measured how many patients with prostate cancer diag-
nosis already have an electronic follow-up form. For the
analysis of the completeness of forms, we considered
patients with a main diagnosis of prostate cancer from
01.01.2009 to 31.12.2009 in the department of urology.
We chose this time range because patients with recent
diagnoses are currently not appointed to follow-up
examination and could bias the result. In total 115 of
the 191 patients have at least one follow-up form with
survival information so that completeness of forms is
60.2%.
Discussion
With our implementation it is now possible to generate
KM-plots from routine data. After exporting follow-up
data sets in a pseudonymized format from the HIS the
physician can start the batch script with the R survival
functions to obtain a resulting PDF-file with the KM-
plots. Both actions can be done by physicians within a
minute and therefore it is a feasible method to get
timely curves from the current data. Up to now, this
procedure was not possible for physicians because data
from routine documentation has to be transferred into
statistical programs for survival analyses to be per-
formed. The idea to enhance the primary information
system is not a new one. Previously, in 1996, Balas et al.
state that “to manage care and improve quality, primary
care computer systems should incorporate these effec-
tive information services” [21]. However, the implemen-
tation of single source systems as described by Kush
et al. [22] is still rare. During our literature search, we
failed to find similar approaches of integrating this kind
of follow-up documentation in the HIS in such a
way that timely survival curves can be generated.
Ene-Iordache et al. analysed regulatory-compliant eCRF
[23] and Embi et al. identified in 2009 a lack of tools for
clinical research activities [24]. By using electronic
point-of-care documentation to generate KM-plots clini-
cal research activities can be supported and the inte-
grated documentation contributes to the single source
approach.
Data Quality Aspects
The measured data quality, especially the completeness
of documented items per form, was high but most of
information was transferred from retrospective data col-
lections (paper based documentation and spreadsheets).
The completeness of the electronic forms in the HIS
(retrospective and current documentation) was only
60.2% so we assume that there are still patients with
missing or paper based documentation. However, to
analyse the completeness of forms more data is needed.
Further analyses will show the differences in complete-
ness of forms between the retrospective collection and
the routine documentation. Chan et al. reviewed data
quality in EHRs of recent studies and reported that data
completeness varied substantially across studies and that
even in the same organisation the amount of missing
data is varying [21]. To measure follow-up completeness
Clark et al. introduced the ratio of the total observed
person-time of follow-up as a percentage of the poten-
tial time of follow-up in a study [11]. Therefore we mea-
sured follow-up completeness of C = 76.9% using this
approach for all prostate cancer patients who underwent
radical prostatectomy in the urology department.
The follow-up documentation is heterogeneous and
therefore the implementation in a local HIS is complex
and time consuming. There is currently no possibility to
reuse captured routine data in electronic study docu-
mentation systems and therefore the advantages of HIS
based documentation are limited. Especially studies with
a high number of study cases (e.g. epidemiological stu-
dies, phase IV studies) are attractive for data re-use. The
Table 4 Completeness of survival data
Attribute Therapy start date Follow-up Status Follow-up date All three available
Routine cases 207
Available 204 207 183 180
Completeness 98.5% 100% 88.4% 86.6%
Retrospective Cases 758
Available 738 743 727 701
Completeness 97.3% 98% 95.9% 92.4%
Total Cases 965
Available 942 950 910 881
Completeness 97.6% 98.5% 94.3% 91.3%
Completeness was measured for routine cases (207) and retrospective cases (758) separately. In total therapy date and follow-up status is relatively complete for
all patients (> 97%), follow-up date was available for 94.3% of the patients. Imprecise date items (follow-up month and follow-up year available) are considered.
Survival information was available for 91.3% of the patients.
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intervals (depending on the disease). The HIS-based
approach adds the functionality to notify the treating
physicians of required documentation activities. We
plan to integrate work lists which show all patients
without a follow-up form in the last year. This approach
could be extended by an automated creation of forms in
the HIS related to the follow-up intervals. Survival infor-
mation in the HIS can be re-used for physician letters.
Our approach of follow-up documentation is generic
and we intend to extend it to other departments and
diseases. If the follow-up information is available for
many patients it can also be used for patient recruit-
ment for clinical trials [25-28] as attributes like survival
status are now documented in a structured way within
the HIS and can be used as inclusion or exclusion
criteria.
I nas h o r tt i m ef r a m e2 2 3c a s e sw e r ed o c u m e n t e d
during routine documentation which indicates a good
clinical acceptance. In addition 806 cases were com-
pleted retrospectively in order to have the entire follow-
up documentation electronically available showing the
need for HIS based follow-up documentation. Struc-
tured documentation of follow-up items should there-
fore be a standard functionality in HIS.
Conclusion
Different follow-up forms can be united in a compre-
hensive module which is suitable for oncological dis-
eases. The integration in the local HIS is feasible and
provides possibilities to reuse this information for qual-
ity control and clinical research (single source) by gener-
ating timely survival curves from routine data.
Additional material
Additional file 1: ODM Follow-up form. This xml-file contains the
follow-up form in the ODM format (v1.3.1).
Additional file 2: R-Code. This file contains the R-Code for the survival
analysis.
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